USFDA approval of Verzenio to treat certain advanced/metastatic breast cancers
The US Food and Drug Administration approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor... Read More
Lilly and Merck’s Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA Combination Trial
Eli Lilly and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib... Read More